In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS, enjoy another 101 days of free consultation

 

Coronary microvascular dysfunction is associated with poor glycemic control in women with diabetes presenting with chest pain and non-obstructive coronary artery disease

Session The cardiovascular dangers of age and sex

Speaker Jaskanwal Deep Sara

Congress : ESC Congress 2019

  • Topic : cardiovascular disease in special populations
  • Sub-topic : Cardiovascular Disease in Women
  • Session type : Advances in Science
  • FP Number : 5879

Authors : JD Sara (Rochester,US), R Taher (Haifa,IL), N Kolluri (Rochester,US), A Vella (Rochester,US), LO Lerman (Rochester,US), A Lerman (Rochester,US)

Authors:
JD Sara1 , R Taher2 , N Kolluri1 , A Vella1 , LO Lerman1 , A Lerman1 , 1Mayo Clinic - Rochester - United States of America , 2Rambam Health Care Campus, Endocrinology - Haifa - Israel ,

Citation:

Background

Patients with type 2 diabetes are at an increased risk of cardiovascular events compared to individuals without diabetes.  The role glycemic control plays in reducing cardiovascular risk remains uncertain.  Coronary microvascular dysfunction (CMD) is more frequent in women compared to men, is prevalent in patients with type 2 diabetes and is linked to adverse cardiovascular events.  We compared the association between CMD and glycemic control across sexes in patients with chest pain and non-obstructive coronary artery disease (CAD).

Methods

Patients with chest pain who were found to have non-obstructive CAD (stenosis < 40%) at angiography underwent an invasive assessment of endothelial-independent and endothelial–dependent coronary microvascular function.  Using a Doppler guidewire, endothelial-independent microvascular function was assessed by measuring the coronary flow velocity in response to intracoronary adenosine and comparing this to baseline to calculate the coronary flow reserve ratio (CFRAdn).  A CFRAdn = 2.5 was considered abnormal.  Endothelial-dependent microvascular function was assessed by measuring the percent change in coronary blood flow in response to intracoronary infusions of acetylcholine (%?CBFAch), with a %?CBFAch = 50% considered abnormal.  Patients were classified as having normal versus abnormal CFRAdn and %?CBFAch.  Measurements of HbA1c and fasting serum glucose were obtained at the time of catheterization and compared between groups after stratification by sex.

Results

Between 1993 and 2012, 1,469 patients (mean age 50.4 years, 35% male) underwent coronary angiography and invasive testing for CMD, of which 129 (8.8%) had type 2 diabetes.  Fifty one (39.5%) had an abnormal %?CBFAch and 49 (38.0%) had an abnormal CFRAdn.  Conventional cardiovascular risk factors did not vary significantly between groups.  Females with an abnormal CFRAdn or abnormal %?CBFAch had a significantly higher HbA1c compared to those with a normal CFRAdn or %?CBFAch respectively: HbA1c % (standard deviation) 7.4 (2.1) vs. 6.5 (1.1), p=0.035 and 7.3 (1.9) vs. 6.4 (1.2), p=0.022, respectively.  Females with an abnormal CFRAdn had significantly higher fasting serum glucose concentrations compared to those with a normal CFRAdn: fasting serum glucose mg/dL (standard deviation) 144.4 (55.6) vs. 121.9 (28.1), p=0.035.  These effects were not observed in men.  Amongst female diabetics, a higher HbA1c was significantly associated with any CMD after adjusting for covariates: odds ratio (95% confidence interval) 1.69 (1.01 – 2.86) p=0.049; and a fasting serum glucose > 140 mg/dL was significantly associated with an abnormal CFRAdn, 4.28 (1.43 – 12.81).

Conclusion

Poor glycemic control is associated with CMD in females with diabete who present with chest pain and non-obstructive CAD.  These findings highlight the importance of sex-specific risk stratification models and treatment strategies when managing cardiovascular risk in diabetics.

This content is currently on FREE ACCESS, enjoy another 101 days of free consultation

 



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are